Although these findings are promising, there remains lack of evidence of a systemic antisense effect; this is clinically important since a treatment for FSHD will need to suppress DUX4 expression in a large number of skeletal muscles. Here, DUX4 is linked to facioscapulohumeral muscular dystrophy.